Xeris Biopharma Holdings
XERS
50 hedge funds and large institutions have $193M invested in Xeris Biopharma Holdings in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 10 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
20% more capital invested
Capital invested by funds: $161M → $193M (+$32.2M)
3.17% more ownership
Funds ownership: 59.43% → 62.6% (+3.2%)
2% more funds holding
Funds holding: 49 → 50 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$10.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.37M |
| 3 |
BlackRock
New York
|
+$3.66M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.92M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$853K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.21M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1M |
| 3 |
Two Sigma Investments
New York
|
-$753K |
| 4 |
Morgan Stanley
New York
|
-$552K |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$425K |
XERS Hedge Fund Activity: Q2 2019 in Review
50 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2019, worth a combined $193M — up 20% from $161M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XERS positions and 10 closed out — a net gain of 3 holders — while 21 added to existing stakes and 8 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $10.5M. The largest seller was Millennium Management, exiting entirely with an estimated $1.21M sold.
- 50 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2019, up from 49 in Q1 2019.
- Funds reported $193M of Xeris Biopharma Holdings stock for Q2 2019, up 20% quarter-over-quarter.
- 13 funds opened new Xeris Biopharma Holdings positions in Q2 2019 and 10 closed out, a net change of +3 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2019 was Invesco, an estimated $10.5M added.
- The largest Xeris Biopharma Holdings seller in Q2 2019 was Millennium Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q2 2019.